McGraw Hill Q2 revenue falls 5.5% as K-12 declines

By Reuters News


Overview

  • US education solutions provider's fiscal Q2 revenue fell 5.5% yr/yr, but topped company expectations

  • Adjusted EBITDA margin fell to 39.6% from 42.8%

  • Digital revenue rose 2.6% yr/yr, supported by AI tool adoption and platform growth


Outlook

  • McGraw Hill reaffirms FY 2027 revenue guidance of $2.115 bln to $2.175 bln

  • Company maintains FY 2027 re-occurring revenue outlook of $1.587 bln to $1.627 bln

  • McGraw Hill expects FY 2027 adjusted EBITDA between $750 mln and $790 mln


Result Drivers

  • DIGITAL REVENUE GROWTH - Co said digital revenue rose 2.6% yr/yr, driven by strong retention, learning platform adoption and increased AI tool usage

  • HIGHER EDUCATION MARKET SHARE - Co said Higher Education segment revenue grew 0.2% yr/yr, citing continued market share gains and value-based pricing momentum

  • K-12 MATH WEAKNESS - Co said K-12 segment revenue fell 9.6% yr/yr, as strength in Science and ELA was offset by lower anticipated capture rates in select Math markets


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q2 Revenue

$632.21 mln

Q2 EPS

$0.45

Q2 Adjusted Net Income

$144.56 mln

Q2 Net Income

$86.38 mln

Q2 Adjusted EBITDA

$250.62 mln

Q2 Adjusted EBITDA Margin

39.60%


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 12 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the consumer publishing peer group is "buy"

  • Wall Street's median 12-month price target for McGraw Hill, Inc. is $17.00, about 33.2% above its November 4 closing price of $12.76

  • The stock recently traded at 6 times the next 12-month earnings vs. a P/E of 6 three months ago


Reuters Recommended Reads

  • Nov 4 - HMH Holding Q3 revenue falls on lower volume across product

  • Nov 5 - Strategic Education Q3 revenue rises 1.6%, slightly misses estimates

  • Nov 4 - Charles River Laboratories Q3 revenue beats estimates, lifts 2026 outlook


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.